Tetrahedron 64 (2008) 5139-5146

Contents lists available at ScienceDirect

Tetrahedron

journal homepage: www.elsevier.com/locate/tet

New strategies for the synthesis of heteroannulated 2-pyridinones, substituted 2-quinolinones and coumarins from dehydroamino acid derivatives

Maria João R.P. Queiroz*, Ana S. Abreu, Ricardo C. Calhelha, M. Solange D. Carvalho, Paula M.T. Ferreira*

Centro de Química, Universidade do Minho, Campus de Gualtar, 4710-057 Braga, Portugal

ARTICLE INFO

Article history: Received 31 January 2008 Received in revised form 13 March 2008 Accepted 17 March 2008 Available online 21 March 2008

Keywords: Dehydroamino acids Suzuki coupling Intramolecular cyclizations Heteroannulated 2-pyridinones 2-Quinolinones Coumarins

ABSTRACT

Several heteroannulated pyridinones were prepared from the methyl esters of *N*-Boc- β , β -diheteroaryldehydroalanines by treatment with acetic acid. The latter were obtained by a bis-Suzuki coupling of a β , β -dibromodehydroalanine with heteroarylboronate compounds. The products were obtained in good yields and the cyclization reaction involves the nucleophilic attack of one of the heteroaromatic rings on the carbonyl of the Boc group. The scope of this reaction was extended to the *Z*-isomer of *N*-Boc- β -heteroaryldehydrophenylalanines to give 4-phenylpyridinones. A tandem Suzuki coupling-cyclization protocol was developed for the synthesis of 2-quinolinones and coumarins. Thus, β -brominated dehydroamino acids were reacted with 2-(pinacolboronate)aniline or phenol in a one-pot Suzuki coupling of lolwed by lactamization or lactonization to give the corresponding 3-amino-2-quinolinones or 3-aminocoumarins in good to high yields. This type of strategy was also applied to the synthesis of 2-quinolinones and coumarins linked in position-3 to amino acids, using as starting materials brominated dehydropeptides.

© 2008 Elsevier Ltd. All rights reserved.

1. Introduction

Ring fused 2-pyridinones involving the nitrogen atom have been used as lead compounds for the preparation of several type of drugs such as selective anticancer agents,¹ antiviral agents² or inhibitors of A_β-peptide aggregation, which play an important role in amyloid formation in Alzheimer's disease.³

Several thieno[2,3-*b*]pyridine-6(7*H*)-ones were prepared by Berger et al. from substituted methyl 2-aminothiophene-3-carboxylates and phenylacetyl chloride to give amides that subsequently cyclized using potassium hexamethyldisilazide in THF at low temperatures. These thienopyridinones were designed by a bioisosteric approach with 3-phenyl-4-hydroxy-quinolin-2-(1*H*)-one by replacement of the benzene nucleus by thiophene and are cytoprotectants and inhibitors of the glycine binding to the *N*-Methyl-D-aspartate (NMDA) receptor.⁴

A series of 2-quinolinones have been synthesized from substituted anilines and diethylmalonate in diphenylether at 250 °C and, were evaluated as non-nucleoside HIV-1 inhibitors of

* Corresponding authors.

reverse transcriptase, some of them showing activity against drug-resistant mutants.⁵

Heck et al.⁶ prepared 2-quinolinones from 2-iodoanilines and dimethyl maleate using $Pd(OAc)_2$ and NEt_3 . Recently, Cho and Kim used a similar approach to obtain the same type of quinolinones from 2-iodoanilines and dialkyl itaconates.⁷

The coumarin moiety is present in several natural products exhibiting a broad range of biological activities, including anticancer⁸ and anti-HIV.⁹ Coumarins have also been used as luminescent probes,¹⁰ photostable laser dyes¹¹ and triplet sensitizers.¹²

Larock and Kadnikov reported the synthesis of coumarins¹³ and 2-quinolinones¹⁴ by palladium-catalyzed carbonylative annulation of internal alkynes with *o*-iodophenols or *o*-iodoanilines.

More recently, Cachi et al. prepared 4-aryl-2-quinolinones¹⁵ and 4arylcoumarins¹⁶ from *o*-bromocinnamamide or alkyl 3-(*o*-hydroxyaryl)acrylates and aryl iodides and bromides using Pd(OAc)₂ and a molten tetra(*n*-butyl)ammonium acetate/tetra(*n*-butyl)ammonium bromide. These domino processes involve in the first case sequential catalytic cycles of a Heck reaction followed by an intramolecular Buchwald–Hartwig C–N bond forming reaction and in the second case a Heck reaction and a nucleophilic attack of the OH group in the carbonyl of the ester.

In the course of our long experience in dehydroamino acid chemistry and metal-mediated reactions, we have synthesized





E-mail addresses: mjrpq@quimica.uminho.pt (M.J.R.P. Queiroz), pmf@quimica.uminho.pt (P.M.T. Ferreira).

^{0040-4020/\$ –} see front matter \odot 2008 Elsevier Ltd. All rights reserved. doi:10.1016/j.tet.2008.03.057

a large variety of new heterocyclic compounds. Thus, by reacting β -bromo or β , β -dibromodehydroamino acid derivatives with aryl or heteroarylboronic acids or boronates under Suzuki cross-coupling conditions we were able to prepare β , β -disubstituted dehydroamino acids, which were successfully cyclized to thienoindoles, benzo[*b*]thienopyrroles and indoles using an unprecedent metal-assisted C–N intramolecular cyclization.^{17–19}

Here, we report an important method for the synthesis of new heteroannulated 2-pyridinones and substituted 2-quinolinones and coumarins using Suzuki and Suzuki–Miyaura cross-couplings²⁰ and intramolecular cyclizations, taking advantage of the reactivity of the amino acid protecting groups. Although several palladium-catalyzed reactions have been used in the synthesis of heterocycles,²¹ to our knowledge this is the first time this strategy was successfully applied to dehydroamino acids and dehydropeptides.

2. Results and discussion

Several new β , β -bis-heteroaryldehydroalanines were prepared by a bis-Suzuki cross-coupling of β , β -dibromodehydroalanine **1**, earlier prepared by us,²² with heteroarylboronated compounds, in good to excellent yields (Scheme 1). The conditions used for the coupling of potassium 3-trifluoroboratethiophene were those described by Molander and Fumagalli in a palladium-catalyzed Suzuki cross-coupling of potassium aryl and heteroaryltrifluoroborates with alkenyl bromides.²³ The other Suzuki couplings were carried out using conditions earlier developed by us.¹⁹

The coupling products **2–5** were treated with acetic acid in DMF at 160 °C (Scheme 1). Compounds **2** and **3** afforded the heteroannulated 2-pyridinones **6** and **7** in good yields, by nucleophilic attack of position-2 of the thiophene or furan rings on the carbonyl of the Boc group with loss of *t*-BuOH. This constitutes, as far as our knowledge, a new method for the synthesis of this type of compounds. When compounds **4** and **5** were subjected to the same conditions, no lactamization occurred and the only products obtained were the very unstable free amines **8** and **9** resulting from cleavage of the Boc group (Scheme 1). This can be due to the fact that position-3 is not so nucleophilic as position-2 in furan and thiophene rings.

Having these results in hand, we decided to apply the same methodology to our previously synthesized β , β -bis(benzo[*b*]thienyl)dehydroalanines **10** and **11**.¹⁷ The corresponding heteroannulated 2-pyridinones **12** and **13** were obtained in good yields (Scheme 2) due to the fact that in the benzo[*b*]thiophene ring position-2 and 3 reacted almost in the same way.



Scheme 2. (iii) 10 equiv CH₃COOH, DMF, 160 °C.

The same approach was applied to the synthesis of heteroannulated pyridinones **16**, **18** and **20** from β -thienyl or benzo[*b*]thienyldehydrophenylalanines **15**, **17** and **19** increasing the scope of this reaction (Scheme 3). However, the product yields were slightly lower when compared with those obtained for compounds **7**, **12** and **13**.

The β -brominated dehydroamino acids were also used as precursors of 2-quinolinones. Thus, by reacting the former with 2-(pinacolboronate)aniline, we were able to obtain compounds **21**, **22**, **24** and **25** in a tandem one-pot Suzuki cross-coupling and lactamization, which occur by nucleophilic attack of the NH₂ on the carbonyl of ester group with loss of methanol (Table 1).

The β , β -dibromodehydroalanine **1** gave quinolinone **21** as major product, after a bis-Suzuki coupling and lactamization and quinolinone **22** as minor product, possibly resulting from the reduction of one of the vinyl-Pd-Br species (Entry 1, Table 1).

Compound **E-23** gave with identical conditions but using 1.3 equiv of 2-(pinacolboronate)aniline the corresponding quinolinone **24** in an excellent yield (entry 2, Table 1). Using the conditions already applied by us in Suzuki couplings of sterically hindered substrates (condition C, namely 2-(dicyclohexylphosphane)biphenyl as ligand and Ba(OH)₂·8H₂O as base),¹⁸ the 2-quinolinone **25** was obtained from **E-14** in 50% yield with cleavage of the Boc group (entry 3, Table 1). This may due to the use of a stronger base and higher temperature.



Scheme 1. (i) 20 mol % PdCl₂(dppf)·CH₂Cl₂ (1:1), 1.4 equiv Cs₂CO₃, THF/H₂O (1:1); (ii) 4 mol % PdCl₂(dppf)·CH₂Cl₂ (1:1), 6 equiv K₂CO₃, toluene/H₂O (2.7:1); (iii) 10 equiv CH₃COOH, DMF, 160 °C.



Scheme 3. (ii) 2 mol % PdCl₂(dppf) · CH₂Cl₂ (1:1), 6 equiv K₂CO₃, toluene/H₂O (2.7:1); (iii) 10 equiv CH₃COOH, DMF, 160 °C.

Table 1

Synthesis of substituted 2-quinolinones by one-pot Suzuki coupling and lactamization



A: 5 equiv 2-(pinacolboronate)aniline, 20 mol % $PdCl_2(dppf)\cdot CH_2Cl_2$ (1:1), 1.4 equiv Cs2CO3, THF/H2O (1:1), 90 °C.

B: 1.3 equiv 2-(pinacolboronate)aniline, 10 mol % PdCl_2(dppf) \cdot CH_2Cl_2 (1:1), 1.4 equiv Cs2CO3, THF/H2O (1:1), 90 $^\circ$ C.

C: 1.3 equiv 2-(pinacolboronate)aniline, 5 mol % Pd(OAc)₂, 20 mol % 2-(dicyclohex-ylphosphane)biphenyl, 3 equiv $Ba(OH)_2 \cdot 8H_2O$, dioxane, 120 °C.

Compound **Z-14** was also reacted with 2-(pinacolboronate)aniline using conditions B and only gave the Suzuki coupling product **26** in 51% yield.



Using a similar methodology, it was also possible to obtain several substituted coumarins using 2-(pinacolboronate)phenol as coupling component (Table 2).

When β_{β} -dibromodehydroalanine **1** was used as coupling component (entry 1, Table 2), we have obtained the coumarin **27** in good yield, adding a KHSO₄ 1 M solution to acidify the reaction mixture. In this case, the product resulting from elimination of a bromine atom was not isolated as observed in the reaction of compound **1** with 2-(pinacolboronate)aniline.

Coumarins **28** and **29** were obtained from compounds *E*-**23** and *E*-**14**, respectively, in excellent yields (entries 2 and 3, Table 2). Compound *E*-**30**, gave coumarin **31** in good yield with cleavage of the 4-nitrobenzyloxycarbonyl group [Cbz(NO₂)].

We have also tried this reaction with β -brominated dehydrodipeptides **32**²⁶ and **33**, which were obtained by bromination of the corresponding dehydrodipeptides with *N*-bromosuccinimide (NBS) followed by treatment with triethylamine. Compound **32** reacted with 2-(pinacolboronate)phenol to give coumarin **34** in 53% yield. The 2-quinolinone **35** was obtained in 60% yield by reacting the dehydrodipeptide **33** with 2-(pinacolboronate)aniline (Scheme 4).

These results show that brominated dehydropeptides are also good substrates for this type of reactions giving interesting coumarins and 2-quinolinones linked in position-3 to an amino acid derivative.

3. Conclusions

We have developed new and efficient strategies for the synthesis of heteroannulated 2-pyridinones, substituted 2-

Table 2 Synthesis of substituted coumarins by one-pot Suzuki coupling and lactonization

R ^{2-N} COOCH ₃ R ¹ Br	Suzuki coupling OH	
$R^1 = Br, R^2 = Boc$ $R^1 = CH_3 \text{ or } C_6H_5, R^2 = Boc$ $R^1 = CH_3, R^2 = Cbz(NO_2)$	O B O L	$R^3 = H \text{ or Boc}$ $R^4 = CH_3 \text{ or aryl}$ 27-29 , 31



A: 5 equiv 2-(pinacolboronate)phenol, 20 mol % PdCl_2(dppf) \cdot CH_2Cl_2 (1:1), 1.4 equiv Cs_2CO_3, THF/H_2O (1:1), 90 $^\circ$ C.

B: 1.3 equiv 2-(pinacolboronate)phenol, 10 mol % PdCl₂(dppf) \cdot CH₂Cl₂ (1:1), 1.4 equiv Cs₂CO₃, THF/H₂O (1:1), 90 °C.

quinolinones and coumarins using brominated dehydroamino acids as building blocks. As far as our knowledge, it is the first time that these compounds were prepared using Suzuki crosscouplings of aryl or heteroarylboron compounds with β -bromo or β , β -dibromodehydroamino acids followed by intramolecular



cyclization. The latter occurs by nucleophilic attack either by the substituents (NH_2 or OH) on the carbonyl of the ester or by the heteroaromatic ring on the carbonyl of the Boc group.

The tandem one-pot Suzuki coupling and intramolecular cyclization methodology, which takes advantage of the presence of an ester as carboxylic acid protecting group, was also applied successfully to brominated dehydropeptides giving coumarins and 2-quinolinones linked to amino acids.

The new compounds obtained are heteroannulated 2-pyridinones, 2-quinolinones and coumarins, and therefore may have several interesting biological applications.

4. Experimental

4.1. Suzuki couplings

4.1.1. Boc- $\Delta Ala[\beta,\beta-bis-(fur-3-yl)]$ -OMe (2)

To a solution of *N-tert*-butoxycarbonyl-,β,β-dibromodehydroalanine [Boc- Δ Ala(β , β -Br)-OMe] $\mathbf{1}^{22}$ (150 mg, 0.418 mmol) in 4 mL of THF/H₂O (1:1), the 3-(pinacolboronate)furan (5 equiv), Cs₂CO₃ (1.4 equiv) and PdCl₂(dppf)·CH₂Cl₂ (1:1) (20 mol %) were added and the mixture was heated at 90 °C for 4 h. THF was removed under reduced pressure and the residue was dissolved in ethyl acetate (25 mL). The organic layer was washed with water and brine (2×10 mL each), dried over MgSO₄ and evaporated at reduced pressure to give an oil. Column chromatography using solvent gradient from neat petroleum ether to 40% diethyl ether/petroleum ether gave compound 2 (104 mg, 75%) as a vellow solid, mp 157–159 °C; ¹H NMR (300 MHz, CDCl₃) δ 1.47 (s, 9H, CH₃Boc), 3.68 (s, 3H, OCH₃), 6.21 (br s, 1H, NH), 6.31 (m, 1H, ArH), 6.51 (br s, 1H, ArH), 7.35 (m, 1H, ArH), 7.39 (m, 1H, ArH), 7.43 (m, 1H, ArH), 7.47 (m, 1H, ArH); ¹³C NMR (75.4 MHz, CDCl₃) δ 28.1 [C(CH₃)₃], 52.1 (OCH₃), 81.3 [OC(CH₃)₃], 110.5 (CH), 111.1 (CH), 115.9 (C), 123.0 (C), 123.3 (C), 124.4 (C), 141.5 (CH), 142.9 (CH), 143.3 (CH), 143.5 (CH), 152.6 (C=O), 166.3(C=O); MS (FAB) m/z (%) 335 (M⁺+2), 334 (M⁺+1), 333 (M⁺); HRMS m/z [M⁺+H] calcd for C₁₇H₂₀NO₆ 334.1291, found 334.1288.

4.1.2. Boc- $\Delta Ala[\beta,\beta-bis-(thien-3-yl)]$ -OMe (3)

To a solution of compound 1 (101 mg, 0.280 mmol) in 2.05 mL of toluene/H2O (2.7:1), potassium 3-thiophene trifluoroborate (3.5 equiv), K₂CO₃ (6 equiv) and PdCl₂(dppf)·CH₂Cl₂ (4 mol %) were added, and the mixture was heated at 90 °C for 3 h 30 min. Toluene was removed under reduced pressure and the residue was dissolved in ethyl acetate (25 mL). The organic layer was washed with water and brine (2×10 mL each), dried over MgSO₄ and evaporated at reduced pressure to give an oil. Column chromatography using solvent gradient from neat petroleum ether to 40% diethyl ether/ petroleum ether gave compound 3 (101 mg, 99%) as a brown solid, mp 124–126 °C; ¹H NMR (300 MHz, CDCl₃) δ 1.47 (s, 9H, CH₃Boc), 3.61 (s, 3H, OCH₃), 6.23 (br s, 1H, NH), 6.87 (dd, *J*=5.0 and 1.2 Hz, 1H, ArH), 7.08 (dd, J=5.0 and 1.2 Hz, 1H, ArH), 7.14 (dd, J=3.0 and 1.2 Hz, 1H, ArH), 7.20 (dd, J=3.0 and 1.2 Hz, 1H, ArH), 7.26 (dd, J=5.0 and 3.0 Hz, 1H, ArH), 7.36 (dd, J=5.0 and 3.0 Hz, 1H, ArH); ¹³C NMR (75.4 MHz, CDCl₃) δ 28.1 [C(CH₃)₃], 52.1 (OCH₃), 81.4 [OC(CH₃)₃], 122.7 (C), 124.2 (CH), 125.2 (CH), 126.0 (CH), 126.5 (CH), 128.2 (CH), 128.4 (CH), 138.4 (C), 139.6 (C), 152.6 (C=O), 166.5 (C=O); MS (FAB) *m*/*z* 367 (M⁺+2), 366 (M⁺+1), 365 (M⁺); HRMS [M⁺+H] *m*/*z* calcd for C17H20NO4S2 366.0834, found 366.0827.

4.1.3. Boc- $\Delta Ala[\beta,\beta-bis-(fur-2-yl)]$ -OMe (4)

To a solution of compound **1** (150 mg, 0.418 mmol) in 4 mL of THF/H₂O (1:1), fur-2-ylboronic acid (8 equiv), Cs_2CO_3 (1.4 equiv) and PdCl₂(dppf)·CH₂Cl₂ (1:1) (20 mol%) were added, and the mixture was heated at 90 °C for 3 h. THF was removed under reduced pressure and the residue was dissolved in ethyl acetate

(25 mL). The organic layer was washed with water and brine (2×10 mL each), dried over MgSO₄ and evaporated at reduced pressure to give an oil. Column chromatography using solvent gradient from neat petroleum ether to 40% diethyl ether/petroleum ether gave compound **4** (121 mg, 87%) as an oil; ¹H NMR (300 MHz, CDCl₃) δ 1.49 (s, 9H, CH₃Boc), 3.68 (s, 3H, OCH₃), 6.34 (br d, *J*=3.3 Hz, 1H, ArH), 6.38 (br d, *J*=3.3 Hz, 1H, ArH), 6.42–6.43 (m, 1H, ArH), 6.46–6.48 (m, 1H, ArH), 7.44 (d, *J*=1.8 Hz, 1H, ArH), 7.54 (d, *J*=1.8 Hz, 1H, ArH); ¹³C NMR (75.4 MHz, CDCl₃) δ 28.1 [C(CH₃)₃], 52.3 (OCH₃), 81.8 [OC(CH₃)₃], 110.9 (CH), 111.0 (CH), 111.7 (CH), 112.5 (CH), 126.7 (C), 142.7 (CH), 142.9 (CH), 144.1 (C), 148.8 (C), 150.6 (C), 152.0 (C=O), 165.4 (C=O); MS (FAB) *m*/*z* 335 (M⁺+2), 334 (M⁺+1), 333 (M⁺), 233 (M⁺-Boc); HRMS [M⁺+H] *m*/*z* calcd for C₁₇H₂₀NO₆ 334.1291, found 334.1285.

4.1.4. Boc- $\Delta Ala[\beta,\beta-bis-(thien-2-yl)]$ -OMe (5)

To a solution of compound 1 (150 mg, 0.418 mmol) in (4 mL) THF/H₂O (1:1), thien-2-ylboronic acid (8 equiv), Cs₂CO₃ (1.4 equiv) and PdCl₂(dppf)·CH₂Cl₂ (1:1) (20 mol%) were added, and the mixture was heated at 90 °C for 7 h. THF was removed under reduced pressure and the residue was dissolved in ethyl acetate (25 mL). The organic layer was washed with water and brine (2×10 mL each), dried over MgSO₄ and evaporated at reduced pressure to give an oil. Column chromatography using solvent gradient from neat petroleum ether to 30% diethyl ether/petroleum ether gave compound **5** (85.0 mg, 56%) as an oil; ¹H NMR (300 MHz, CDCl₃) δ 1.49 (s, 9H, CH₃Boc), 3.60 (s, 3H, OCH₃), 6.43 (br s, 1H, NH), 6.97-7.11 (m, 4H, ArH), 7.36 (dd, J=5.0 and 1.5 Hz, 1H, ArH), 7.44 (dd, I=5.0 and 1.5 Hz, 1H, ArH); ¹³C NMR (75.4 MHz, CDCl₃) δ 28.1 [C(CH₃)₃], 52.2 (OCH₃), 81.7 [OC(CH₃)₃], 119.6 (C), 125.9 (C), 126.5 (CH), 127.2 (2×CH), 128.2 (CH), 128.4 (CH), 130.1 (CH), 140.2 (C), 140.5 (C), 152.5 (C=O), 165.9 (C=O); MS (FAB) m/z 367 (M⁺+2), 366 (M⁺+1), 365 (M⁺); HRMS [M⁺+H] m/z calcd for C₁₇H₂₀NO₄S₂ 366.0834, found 366.0850.

4.2. General procedure for the synthesis of 2-pyridinones

In a Schlenk tube containing a solution of compounds **2**, **3**, **10**,¹⁷ **11**,¹⁷ **15**, **17**²⁴ or **19**²⁴ in dry DMF (0.1 M), glacial acetic acid (10 equiv) was added and the mixture was stirred under Ar at 160 °C for several hours. After cooling, ethyl acetate (30 mL) was added and the solution was washed with water and brine (2×10 mL each), dried over MgSO₄ and the removal of solvent under reduced pressure gave an oil.

4.2.1. Methyl 4-(fur-3-yl)-6H-furo[2,3-c]pyridin-7-one-5-carboxylate (**6**)

Compound **6** was prepared from compound **2** (100 mg, 0.300 mmol) according to the general procedure described above and heating for 5 h 30 min. Column chromatography using solvent gradient from diethyl ether to 50% chloroform/diethyl ether gave compound **6** (42.0 mg, 52%) as a beige solid, mp 204–205 °C; ¹H NMR (300 MHz, CDCl₃) δ 3.84 (s, 3H, OCH₃), 6.48 (dd, *J*=2.4 and 0.6 Hz, 1H, ArH), 6.65 (d, *J*=1.8 Hz, 1H, ArH), 7.54–7.56 (m, 2H, ArH), 7.80 (d, *J*=1.8 Hz, 1H, ArH), 9.89 (br s, 1H, NH); ¹³C NMR (75.4 MHz, CDCl₃) δ 53.0 (OCH₃), 108.4 (CH), 112.2 (CH), 112.7 (C), 118.7 (C), 125.7 (C), 135.6 (C), 141.2 (CH), 142.7 (CH), 144.9 (C), 148.9 (CH), 151.7 (C=O), 161.8 (C=O); MS *m*/*z* 259 (M⁺), 244 (M⁺–CH₃), 215 (M⁺–44), 69 (M⁺–190); HRMS *m*/*z* M⁺ calcd for C₁₃H₉NO₅ 259.0481, found 259.0483.

4.2.2. Methyl 4-(thien-3-yl)-thieno[2,3-c]pyridin-7-one-5-carboxylate (7)

Compound **7** was prepared from compound **3** (87.0 mg, 0.238 mmol) according to the general procedure described above and heating for 5 h 30 min. The oil obtained was washed with

diethyl ether and compound **7** (47.0 mg, 68%) was obtained as a beige solid, mp 198–200 °C; ¹H NMR (300 MHz, CDCl₃) δ 3.74 (s, 3H, OCH₃), 7.00 (d, *J*=5.4 Hz, 1H, ArH), 7.07 (dd, *J*=5.1 and 1.5 Hz, 1H, ArH), 7.25–7.27 (m, 2H, ArH), 7.44 (dd, *J*=5.1 and 3.0 Hz, 1H, ArH), 7.71 (d, *J*=5.4 Hz, 1H, ArH), 9.45 (br s, 1H, NH); ¹³C NMR (75.4 MHz, CDCl₃) δ 53.1 (OCH₃), 118.3 (C), 124.2 (CH), 125.2 (CH), 126.1 (CH), 126.3 (C), 129.0 (CH), 133.6 (C), 133.7 (CH), 135.0 (C), 147.3 (C), 157.2 (C=O), 162.2 (C=O); MS (EI) *m*/*z* 291 (M⁺), 231 (M⁺–COOMe), 69(M⁺–222); HRMS *m*/*z* M⁺ calcd for C₁₃H₉NO₃S₂ 291.0024, found 291.0026.

4.2.3. $H-\Delta Ala[\beta,\beta-bis-(fur-2-yl)]-OMe$ (8)

Compound **8** was prepared from Boc- Δ Ala-[β , β -bis-(fur-2-yl)]-OMe **4** (0.340 mmol, 113 mg) according to the general procedure described above and heating for 5 h giving the unstable compound **8** (78.0 mg, 98%) as an oil; ¹H NMR (300 MHz, CDCl₃) δ 3.65 (s, 3H, OCH₃), 5.22 (br s, 2H, NH₂), 6.10 (dd, *J*=3.3 Hz, 1H, ArH), 6.25 (dd, *J*=3.3 and 0.9 Hz, 1H, ArH), 6.42–6.44 (m, 2H, ArH), 7.43 (dd, *J*=1.8 and 0.9 Hz, 1H, ArH).

4.2.4. H- $\Delta Ala[\beta,\beta$ -bis-(thien-2-yl)]-OMe (**9**)

Compound **9** was prepared from Boc- Δ Ala-[β , β -bis-(thien-2-yl)]-OMe **5** (0.328 mmol, 120.0 mg) according to the general procedure described above and heating for 3 h 30 min giving the unstable compound **9** (80.0 mg, 92%) as an oil; ¹H NMR (300 MHz, CDCl₃) δ 3.59 (s, 3H, OCH₃), 4.46 (br s, 2H, NH₂), 6.87 (dd, *J*=3.6 and 1.2 Hz, 1H, ArH), 6.97 (dd, *J*=5.3 and 3.6 Hz, 1H, ArH), 7.05 (dd, *J*=5.3 and 3.6 Hz, 1H, ArH), 7.29 (dd, *J*=5.3 and 1.2 Hz, 1H, ArH), 7.33 (dd, *J*=5.3 and 1.2 Hz, 1H, ArH).

4.2.5. Methyl 4-(benzothien-3-yl)-2H-benzothieno[2,3-c]pyridin-1-one-3-carboxylate (**12**)

Compound **12** was prepared from compound **10**¹⁷ (100 mg, 0.215 mmol) according to the general procedure described above and heating for 5 h. Column chromatography using solvent dichloromethane gave compound **12** (40.0 mg, 48%) as a white solid, mp 287–288 °C; ¹H NMR (400 MHz, CDCl₃) δ 3.58 (s, 3H, OCH₃), 6.54 (br d, *J*=8.4 Hz, 1H, ArH), 7.00–7.05 (m, 1H, ArH) 7.29–7.45 (m, 5H, ArH), 7.93 (br d, *J*=8.4 Hz, 1H, ArH), 8.02 (br d, *J*=8.4 Hz, 1H, ArH), 9.93 (br s, 1H, NH); ¹³C NMR (100.6 MHz, CDCl₃) δ 53.3 (OCH₃), 116.5 (C), 122.4 (CH), 123.0 (CH), 123.4 (CH), 124.8 (CH), 125.0 (CH), 125.1 (CH), 125.2 (CH), 125.4 (CH), 127.8 (CH), 128.2 (C), 130.5 (C), 135.4 (C), 135.9 (C), 139.0 (C), 139.4 (C), 140.9 (C), 142.5 (C), 157.6 (C=O), 161.9 (C=O); MS (EI) *m*/*z* 391 (M⁺), 331, 302; HRMS *m*/*z* calcd for C₂₁H₁₃NO₃S₂ 391.0337, found 391.0330.

4.2.6. Methyl 4-(benzothien-2-yl)-2H-benzothieno[3,2-c]pyridin-1-one-3-carboxylate (**13**)

Compound **13** was prepared from compound **11**¹⁷ (100 mg, 0.215 mmol) according to the general procedure described above and heating for 2 h. Column chromatography using dichloromethane gave compound **13** (49.0 mg, 63%) as a beige solid, mp 255–256 °C; ¹H NMR (400 MHz, CDCl₃) δ 3.79 (s, 3H, OCH₃), 7.40–7.61 (m, 5H, ArH), 7.81 (d, *J*=8.0 Hz, 1H, ArH), 7.87–7.93 (m, 2H, ArH), 8.95 (d, *J*=8.0 Hz, 1H, ArH), 9.72 (br s, 1H, NH); ¹³C NMR (100.6 MHz, CDCl₃) δ 53.5 (OCH₃), 114.6 (C), 121.9 (CH), 122.3 (CH), 124.1 (CH), 124.6 (CH), 125.0 (CH), 125.4 (CH), 125.91 (CH), 125.94 (CH), 126.7 (C), 127.0 (CH), 127.5 (C), 136.0 (C), 136.1 (C), 139.4 (C), 139.9 (C), 140.8 (C), 153.8 (C), 157.4 (C=O), 161.4 (C=O). Anal. Calcd for C₂₁H₁₃NO₃S₂: C, 64.43; H, 3.35; N, 3.58; S, 16.38. Found: C, 64.06; H, 3.51; N, 3.59; S, 16.34.

4.2.7. Boc-(Z)- Δ Phe[β -(thien-3-yl)]-OMe (15)

To a solution of compound **Z-14**²⁴ (200 mg, 0.560 mmol) in 4.1 mL toluene/H₂O (2.7:1), the potassium 3-thiophene trifluoroborate (1.3 equiv), K_2CO_3 (6 equiv) and PdCl₂(dppf)·CH₂Cl₂ (1:1) (2 mol %) were added, and the mixture was heated at 90 °C for

3 h 30 min. Toluene was removed under reduced pressure and the residue was dissolved in ethyl acetate (25 mL). The organic layer was washed with water and brine (2×10 mL each), dried over MgSO₄ and evaporated at reduced pressure to give an oil. Column chromatography using solvent gradient from neat petroleum ether to 30% diethyl ether/petroleum ether gave compound **15** (0.183 g, 91%) as a yellow solid, mp 128–130 °C; ¹H NMR (300 MHz, CDCl₃) δ 1.48 (s, 9H, CH₃Boc), 3.50 (s, 3H, OCH₃), 6.23 (br s, 1H, NH), 7.06 (dd, *J*=5.3 and 1.2 Hz, 1H, ArH), 7.14–7.18 (m, 3H, ArH), 7.29–7.36 (m, 4H, ArH); ¹³C NMR (75.4 MHz, CDCl₃) δ 28.1 [C(CH₃)₃], 51.9 (OCH₃), 81.3 [OC(CH₃)₃], 125.2 (C), 125.9 (CH), 126.9 (CH), 127.9 (CH), 128.0 (2×CH), 128.4 (CH), 129.0 (2×CH), 139.2 (C), 139.7 (C), 152.8 (C=O), 166.4 (C=O); MS (FAB) *m*/*z* 361 (M⁺+2), 360 (M⁺+1), 359 (M⁺); HRMS *m*/*z* [M⁺+H] calcd for C₁₉H₂₂NO₄S 360.1270, found 360.1275.

4.2.8. Methyl 4-phenyl-6H-thieno[2,3-c]pyridin-7-one-5-carboxylate (**16**)

Compound **16** was prepared from compound **15** (143 mg, 0.398 mmol) according to the general procedure described above and heating for 4 h. Column chromatography using diethyl ether gave compound **16** as a yellow solid (37.0 mg, 33%), mp 181–183 °C; ¹H NMR (300 MHz, CDCl₃) δ 3.67 (s, 3H, OCH₃), 6.89 (d, *J*=5.4 Hz, 1H, ArH), 7.26–7.30 (m, 2H, ArH), 7.45–7.48 (m, 3H, ArH), 7.69 (d, *J*=5.4 Hz, 1H, ArH), 9.46 (br s, 1H, NH); ¹³C NMR (75.4 MHz, CDCl₃) δ 52.8 (OCH₃), 123.3 (C), 125.8 (C), 126.1 (CH), 128.0 (CH), 128.2 (2×CH), 129.2 (2×CH), 133.6 (CH), 135.8 (C), 147.2 (C), 157.3 (C=O), 162.3 (C=O); MS (FAB) *m*/*z* 287 (M⁺+2), 286 (M⁺+1), 285 (M⁺); HRMS *m*/*z* [M⁺+H] calcd for C₁₅H₁₂NO₃S 286.0538, found 286.0536.

4.2.9. Methyl 4-phenyl-2H-benzothieno[2,3-c]pyridin-1-one-3-carboxylate (18)

Compound **13** was prepared from compound **17** (196 mg, 0.479 mmol) according to the general procedure described above and heating for 5 h. The crude was washed with diethyl ether giving compound **18** (31.0 mg, 20%) as a yellow solid, mp 266–268 °C; ¹H NMR (300 MHz, CDCl₃) δ 3.69 (s, 3H, OCH₃), 6.48 (d, *J*=8.4 Hz, 1H, ArH), 7.09 (t, *J*=8.1 Hz, 1H, ArH), 7.33–7.37 (m, 2H, ArH), 7.44 (t, *J*=8.1 Hz, 1H, ArH), 7.53–7.57 (m, 3H, ArH), 7.93 (d, *J*=8.4 Hz, 1H, ArH), 9.94 (br s, 1H, NH); ¹³C NMR (75.4 MHz, CDCl₃) δ 53.0 (OCH₃), 123.4 (CH), 123.8 (C), 124.9 (CH), 125.9 (CH), 126.3 (C), 127.7 (CH), 128.5 (CH), 128.8 (2×CH), 129.3 (2×CH), 135.7 (C), 135.78 (C), 135.81 (C), 140.7 (C), 142.5 (C), 157.6 (C=0), 162.0 (C=0); MS (FAB) *m/z* 337 (M⁺+2), 336 (M⁺+H), 335 (M⁺), 304 (M⁺–OMe); HRMS *m/z* [M⁺+H] calcd for C₁₉H₁₄NO₃S 336.0694, found 336.0692.

4.2.10. Methyl 4-phenyl-2H-benzothieno[3,2-c]pyridin-1-one-3-carboxylate (**20**)

Compound **20** was prepared from compound **19** (113 mg, 0.287 mmol) according to the general procedure described above and heating for 4 h. The crude was washed with diethyl ether giving compound **20** (33.0 mg, 34%) as a beige solid, mp 282–284 °C; ¹H NMR (400 MHz, CDCl₃) δ 3.72 (s, 3H, OCH₃), 7.38–7.40 (m, 2H, ArH), 7.48–7.59 (m, 5H, ArH), 7.80 (d, *J*=7.6 Hz, 1H, ArH), 8.97 (br d, *J*=7.2 Hz, 1H, ArH), 9.78 (br s, 1H, NH); ¹³C NMR (100.6 MHz, CDCl₃) δ 53.1 (OCH₃), 121.8 (CH), 122.4 (C), 125.6 (C), 125.8 (CH), 126.0 (CH), 126.9 (CH), 128.5 (2×CH), 128.6 (C), 128.7 (CH), 129.1 (2×CH), 129.3 (C), 135.6 (C), 136.1 (C), 140.1 (C), 157.7 (C=O), 161.8 (C=O); MS (FAB) *m*/*z* 337 (M⁺+2), 336 (M⁺+1), 335 (M⁺); HRMS *m*/*z* [M⁺+H] calcd C₁₉H₁₄NO₃S 336.0694, found 336.0687.

4.3. General procedures for the synthesis of 3,4-disubstituted 2-quinolinones and coumarins

Procedure 1. To a solution of compound $1,^{22}$ *E*-14,²⁴ *E*-23,²⁵ *E*-30,²⁶ *E*-32²⁶ or *E*-33 in THF/H₂O (1:1), 2-(pinacolboronate)aniline

or 2-(pinacolboronate)phenol, Cs_2CO_3 (1.4 equiv) and $PdCl_2(dppf) \cdot CH_2Cl_2$ (1:1) were added and the mixture was heated at 90 °C. THF was removed under reduced pressure and the residue was dissolved in ethyl acetate (25 mL). The organic layer was then washed with water and brine (2×10 mL each), dried over MgSO₄ and evaporated at reduced pressure to give an oil.

Procedure 2. A dried Schlenk tube was charged under Ar with dry dioxane (3 mL), **E-14** (0.500 mmol), $Pd(OAc)_2$ (5 mol %), 2-(dicy-clohexylphosphino)biphenyl (20 mol %), $Ba(OH)_2 \cdot 8H_2O$ (3 equiv) and 2-(pinacolboronate)aniline (1.3 equiv). The mixture was heated at 100 °C for 1 h. Water and ethyl acetate were added, the phases were separated, and the aqueous phase was extracted with more ethyl acetate. The organic phases were collected, dried (MgSO₄), filtered and the solvent was evaporated at reduced pressure to give a brown oil, which was subjected to column chromatography.

4.3.1. 3-(tert-Butoxycarbonyl)amino-4-(2-aminophenyl)quinolin-2-one (21) and 3-(tert-butoxycarbonyl)aminoquinolin-2-one (22)

2-Quinolinones 21 and 22 were prepared from compound 1 (72.0 mg, 0.200 mmol), 5 equiv of 2-(pinacolboronate)aniline and 20 mol % PdCl₂(dppf) CH₂Cl₂ (1:1) according to general procedure 1 and heating for 3 h. Crystallization from ethyl acetate gave a brown solid **21** (47.0 mg, 70%), mp 200-202 °C; ¹H NMR (300 MHz, CDCl₃) δ 1.36 (s, 9H, CH₃Boc), 3.80 (br s, 2H, NH₂), 6.51 (br s, 1H, NHBoc), 6.84–6.89 (m, 2H, ArH), 7.03 (dd, J=8.1 and 1.5 Hz, 1H, ArH), 7.09-7.14 (m, 1H, ArH), 7.22-7.32 (m, 2H, ArH), 7.39-7.47 (m, 2H, ArH), 12.38 (br s, 1H, NH); 13 C NMR (75.4 MHz, CDCl₃) δ 28.0 [C(CH₃)₃], 80.4 [OC(CH₃)₃], 116.1 (CH), 116.3 (CH), 118.5 (CH), 119.7 (C), 120.5 (C), 122.8 (CH), 126.4 (C), 127.0 (CH), 129.48 (CH), 129.51 (CH), 129.8 (CH), 136.5 (C), 142.2 (C), 144.4 (C), 153.3 (C=O), 161.1 (C=O); MS (FAB) m/z 353 (M⁺+2), 352 (M⁺+1) 351 (M⁺); HRMS m/z 352.1664 [M⁺+H] (calcd C₂₀H₂₂N₃O₃ 352.1661). Column chromatography of the remaining residue using solvent gradient from neat petroleum ether to 20% diethyl ether/petroleum ether gave 2-quinolinone **22** (5.0 mg, 10%) as a brown solid, mp 178–180 °C; ¹H NMR (300 MHz, CDCl₃) δ 1.58 (s, 9H, CH₃Boc), 7.22-7.27 (m, 1H, ArH), 7.33–7.46 (m, 2H, ArH), 7.57 (d, J=7.8 Hz, 1H, ArH), 7.77 (s, 1H, NHBoc), 8.44 (s, 1H, β-CH), 11.53 (br s, 1H, NH); ¹³C NMR (75.4 MHz, CDCl₃) & 28.3 [C(CH₃)₃], 81.2 [OC(CH₃)₃], 115.4 (CH), 119.3 (CH), 120.9 (C), 123.4 (CH), 127.3 (CH), 127.9 (CH), 128.4 (C), 133.2 (C), 152.7 (C=O), 158.7 (C=O); MS (FAB) *m*/*z* 261 (M⁺+1), 260 (M⁺), 205 (M⁺-C(CH₃)₃); HRMS m/z [M⁺+H] calcd for C₁₄H₁₇N₂O₃ 261.1239, found 261.1244.

4.3.2. 3-(tert-Butoxycarbonyl)amino-4-methylquinolin-2-one (24)

2-Quinolinone **24** was prepared from compound *E*-**23** (60.0 mg, 0.200 mmol), 1.3 equiv of 2-(pinacolboronate)aniline and 10 mol % PdCl₂(dppf)·CH₂Cl₂ (1:1) according to general procedure 1 described above and heating for 3 h. Crystallization from ethyl acetate/petroleum ether gave compound **24** as a brown solid (53.0 mg, 97%), mp 211–213 °C; ¹H NMR (300 MHz, CDCl₃) δ 1.53 (s, 9H, CH₃Boc), 2.47 (s, 3H, CH₃), 7.08 (br s, 1H, NHBoc), 7.22–7.27 (m, 1H, ArH), 7.36–7.46 (m, 2H, ArH), 7.72 (d, *J*=7.8 Hz, 1H, ArH), 12.11 (br s, 1H, NH); ¹³C NMR (75.4 MHz, CDCl₃) δ 15.7 (CH₃), 28.2 [C(CH₃)₃], 80.7 [OC(CH₃)₃], 116.1 (CH), 121.3 (C), 122.8 (CH), 124.7 (CH), 125.4 (C), 129.2 (CH), 135.3 (C), 139.1 (C), 153.6 (C=O), 160.8 (C=O); MS (FAB) *m*/*z* 276 (M⁺+2), 275 (M⁺+1), 274 (M⁺); HRMS *m*/*z* [M⁺+H] calcd for C₁₅H₁₉N₂O₃ 275.1396, found 275.1397.

4.3.3. 3-Amino-4-phenylquinolin-2-one (25)

2-Quinolinone **25** was prepared from compound *E*-14 (175 mg, 0.500 mmol) according to general procedure 2 and heating for 1 h. Column chromatography using solvent gradient from pure petroleum ether to diethyl ether gave compound **25** as a brown solid (59.0 mg, 50%), mp 238–240 °C; ¹H NMR (300 MHz, CDCl₃) δ 4.37 (br s, 2H, NH₂), 7.08–7.11 (m, 2H, ArH), 7.26–7.32 (m, 1H, ArH), 7.38–

7.42 (m, 3H, ArH), 7.46–7.52 (m, 1H, ArH), 7.56–7.62 (m, 2H, ArH), 11.78 (br s, 1H, NH); ¹³C NMR (75.4 MHz, CDCl₃) δ 115.6 (CH), 122.1 (C), 122.2 (C), 122.7 (CH), 124.0 (CH), 125.6 (CH), 128.2 (CH), 129.5 (2×CH), 129.7 (2×CH), 132.1 (C), 133.4 (C), 134.8 (C), 159.2 (C=O); MS *m*/*z* 236 (M⁺), 235 (M⁺–1), 217 (M⁺–19), 190 (M⁺–46); HRMS *m*/*z* M⁺ calcd for C₁₅H₁₂N₂O 236.0950, found 236.0952.

4.3.4. Boc-(Z)- Δ Phe[β -(2-aminophenyl)]-OMe (**26**)

Compound **26** was prepared from **Z-14** (100 mg, 0.280 mmol), 1.3 equiv of 2-(pinacolboronate)aniline and 10 mol % PdCl₂(dppf)·CH₂Cl₂ (1:1) according to general procedure 1 described above and heating for 2 h 30 min. Column chromatography using solvent gradient from pure petroleum ether to 50% diethyl ether in petroleum ether gave compound 26 (53.0 mg, 51%), mp 149–151 °C; ¹H NMR (300 MHz, CDCl₃) δ 1.45 (s, 9H, CH₃Boc), 3.59 (s, 3H, OCH₃), 3.86 (br s, 2H, NH₂), 6.01 (br s, 1H, NH), 6.69-6.76 (m, 2H, ArH), 6.88 (br d J=7.5 Hz, 1H, ArH), 7.12-7.19 (m, 3H, ArH), 7.26-7.30 (m, 3H, ArH); ¹³C NMR (75.4 MHz, CDCl₃) δ 28.1 [C(CH₃)₃], 52.0 (OCH₃), 81.3 [OC(CH₃)₃], 115.8 (CH), 118.3 (CH), 122.5 (C), 126.9 (C), 127.9 (CH), 128.2 (2×CH), 128.6 (2×CH), 129.2 (C), 129.6 (CH), 131.1 (CH), 139.1 (C), 143.9 (C), 153.1 (C=0), 166.2 (C=0); MS (FAB) m/z 370 (M⁺+2), 369 (M^++1) , 251 (M^+-118) ; HRMS m/z $[M^++H]$ calcd $C_{21}H_{25}N_2O_4$ 369.1814, found 369.1822.

4.3.5. 3-(tert-Butoxycarbonyl)amino-4-(2-hydroxyphenyl)-coumarin (**27**)

Coumarin **27** was prepared from compound **1** (72.0 mg. 0.200 mmol), 5 equiv of 2-(pinacolboronate)phenol and 20 mol% PdCl₂(dppf)·CH₂Cl₂ (1:1) according to general procedure 1 and heating for 3 h 30 min. After removing THF under reduced pressure, the residue was dissolved in ethyl acetate (25 mL). The organic layer was washed with a solution of 1 M KHSO₄, water and brine (2×10 mL each), dried over MgSO₄ and evaporated at reduced pressure to give an oil. Crystallization from diethyl ether gave a brown solid **27** (43.0 mg, 61%), mp 194–196 °C; ¹H NMR (300 MHz, acetone- d_6) δ 1.36 (s, 9H, CH₃Boc), 7.03–7.12 (m, 2H, ArH), 7.19-7.32 (m, 3H, ArH), 7.38-7.44 (m, 2H, ArH), 7.59-7.64 (m, 1H, ArH), 8.54 (br s, 1H, NH); 13 C NMR (75.4 MHz, acetone- d_6) δ 28.2 [C(CH₃)₃], 80.1 [OC(CH₃)₃], 117.1 (CH), 117.2 (CH), 120.6 (CH), 120.9 (C), 121.0 (C), 123.6 (C), 125.0 (CH), 128.3 (CH), 130.9 (CH), 131.3 (CH), 131.8 (CH), 146.5 (C), 153.1 (C), 154.3 (C), 155.0 (C), 159.5 (C); MS (FAB) m/z 355 (M⁺+2), 354 (M⁺+1), 353 (M⁺); HRMS m/z $[M^++H]$ calcd $C_{20}H_{20}NO_5$ 354.1341, found 354.1342.

4.3.6. 3-(tert-Butoxycarbonyl)amino-4-methylcoumarin (28)

Compound **28** was prepared from *E*-**23** (100 mg, 0.340 mmol), 1.3 equiv of 2-(pinacolboronate)phenol and 10 mol % PdCl₂(dppf).CH₂Cl₂ (1:1) according to general procedure 1 described above and heating for 3 h 30 min. Column chromatography using solvent gradient from 50% dichloromethane in petroleum ether to neat dichloromethane gave compound **28** (93.0 mg, 99%) as a beige solid, mp 137–139 °C; ¹H NMR (300 MHz, CDCl₃) δ 1.51 (s, 9H, CH₃Boc), 2.40 (s, 3H, CH₃), 6.60 (br s, 1H, NH), 7.29–7.35 (m, 2H, ArH), 7.46–7.51 (m, 1H, ArH), 7.64 (dd, *J*=8.1 and 1.5 Hz, 1H, ArH); ¹³C NMR (75.4 MHz, CDCl₃) δ 15.4 (CH₃), 28.1 [C(CH₃)₃], 81.2 [OC(CH₃)₃], 116.6 (CH), 120.8 (C), 121.0 (C), 124.6 (CH), 124.9 (CH), 130.5 (CH), 141.8 (C), 150.8 (C), 153.1 (C), 159.8 (C); MS *m/z* 275 (M⁺), 201 (M⁺–(CH₃)₃CO), 175 (M⁺–Boc), 146 (M⁺–129); HRMS *m/z* M⁺ calcd for C₁₅H₁₇NO₄ 275.1158, found 275.1152.

4.3.7. 3-(tert-Butoxycarbonyl)amino-4-phenylcoumarin (29)

Coumarin **29** was prepared from compound *E*-**14** (122 mg, 0.340 mmol), 1.3 equiv of 2-(pinacolboronate)phenol and 10 mol % PdCl₂(dppf)·CH₂Cl₂ (1:1) according to general procedure 1 described above and heating for 3 h. Column chromatography using

solvent gradient from neat petroleum ether to 40% diethyl ether/ petroleum ether gave compound **29** (111 mg, 97%) as a white solid, mp 153–154 °C; ¹H NMR (300 MHz, CDCl₃) δ 1.28 (s, 9H, CH₃Boc), 6.14 (br s, 1H, NH), 7.18–7.22 (m, 1H, ArH), 7.29–7.33 (m, 1H, ArH), 7.37–7.40 (m, 3H, ArH), 7.45–7.54 (m, 4H, ArH); ¹³C NMR (75.4 MHz, CDCl₃) δ 27.8 [C(CH₃)₃], 80.8 [OC(CH₃)₃], 116.7 (CH), 120.1 (C), 120.7 (C), 124.4 (CH), 127.1 (CH), 128.5 (2×CH), 128.68 (2×CH), 128.72 (CH), 130.9 (CH), 133.0 (C), 145.9 (C), 151.8 (C), 152.2 (C), 159.9 (C); MS (FAB) m/z 338 (M⁺+1), 282 (M⁺+1–(CH₃)₃C), 238 (M⁺+1–Boc); HRMS m/z [M⁺+H] calcd for C₂₀H₂₀NO₄ 338.1392, found 338.1394.

4.3.8. 3-Amino-4-methylcoumarin (31)

Coumarin **31** was prepared from compound *E*-**30** (110 mg, 0.290 mmol), 1.3 equiv of 2-(pinacolboronate)phenol and 10 mol % PdCl₂(dppf)·CH₂Cl₂ (1:1) according to general procedure 1 and heating for 7 h. Column chromatography using a solvent gradient from neat petroleum ether to 40% diethyl ether/petroleum ether gave compound **31** (24.0 mg, 47%) as a yellow solid, mp 104–106 °C; ¹H NMR (300 MHz, CDCl₃) δ 2.24 (s, 3H, CH₃), 4.18 (br s, 2H, NH₂), 7.24–7.33 (m, 3H, ArH), 7.46–7.50 (m, 1H, ArH); ¹³C NMR (75.4 MHz, CDCl₃) δ 11.7 (CH₃), 116.4 (CH), 118.8 (C), 121.7 (C), 122.5 (CH), 124.5 (CH), 126.9 (CH), 128.9 (C), 148.5 (C), 159.0 (C); MS (EI) *m/z* 175 (M⁺), 146 (M⁺– 29); HRMS M⁺ *m/z* calcd for C₁₀H₉NO₂ 175.0633, found 175.0632.

4.3.9. Boc-Val-Z-⊿Abu-OMe

Boc-Val-*Z*-ΔAbu-OMe was prepared from Boc-Val-Thr-OMe (3.14 g, 10 mmol), *tert*-butylpyrocarbonate (Boc₂O) (2.18 g, 10 mmol) and 4-dimethylaminopyridine (DMAP) (122 mg, 1 mmol,), according to the procedure described by us elsewhere.²⁷ Boc-Val-*Z*-ΔAbu-OMe (2.39 g, 76%) was obtained as white solid, mp 107.5–108.0 °C from diethyl ether/*n*-hexane; ¹H NMR (300 MHz, CDCl₃) δ 0.97 (d, *J*=6.9 Hz, 3H, γ-CH₃Val), 1.02 (d, *J*=6.9 Hz, 3H, γ-CH₃Val), 1.43 (s, 9H, CH₃Boc), 1.75 (d, *J*=7.2 Hz, 3H, γ-CH₃ΔAbu), 2.13–2.25 (m, 1H, β-CHVal), 3.73 (s, 3H, OCH₃), 4.05–4.12 (m, 1H, α-CHVal), 5.18 (d, *J*=8.4 Hz, 1H, NHVal), 6.80 (q, *J*=7.2 Hz, 1H, β-CHΔAbu), 7.61 (s, 1H, NHΔAbu); ¹³C NMR (75.4 MHz, CDCl₃) δ 14.5 (γ-CH₃ΔAbu), 17.7 (γ-CH₃Val), 19.2 (γ-CH₃Val), 28.2 [C(CH₃)₃], 30.7 (β-CHVal), 52.2 (OCH₃), 60.0 (α-CHVal), 80.0 [OC(CH₃)₃], 126.0 (C), 134.5 (β-CHΔAbu), 155.9 (C), 164.7 (C), 170.2 (C). Anal. Calcd for C₁₅H₂₆N₂O₅: C, 57.31; H, 8.34; N, 8.91. Found: C, 57.34; H, 8.15; N, 8.86.

4.3.10. Boc-Val- \triangle Abu(β -Br)-OMe (**Z**- and **E-33**)

Boc-Val-Z-∆Abu-OMe (1.57 g, 5 mmol) was reacted with NBS (0.900 g, 5 mmol) followed by treatment with triethylamine (2.5 equiv) according to the procedure described by us elsewhere²⁶ giving Boc-Val- Δ Abu(β -Br)-OMe (1.88 g, 96%) as a 1:1 mixture of E and Z-isomer. Column chromatography using solvent gradient from neat petroleum ether to 40% diethyl ether/petroleum ether gave Boc-Val-Z- Δ Abu(β -Br)-OMe (**Z-33**) as a white solid, mp 137.5–138.0 °C from diethyl ether/*n*-hexane; ¹H NMR (300 MHz, CDCl₃) δ 0.96 (d, *J*=6.9 Hz, 3H, γ-CH₃Val), 1.07 (d, *J*=6.9 Hz, 3H, γ-CH₃Val), 1.45 (s, 9H, CH₃Boc), 2.16–2.27 (m, 1H, β-CHVal), 2.57 (s, 3H, γ-CH₃ΔAbu), 3.79 (s, 3H, OCH₃), 3.94–4.09 (m, 1H, α-CHVal), 5.05 (d, J=8.7 Hz, 1H, NHVal), 7.75 (s, 1H, NH Δ Abu); ¹³C NMR $(75.4 \text{ MHz}, \text{ CDCl}_3) \delta 17.6 (\gamma-\text{CH}_3\text{Val}), 19.1 (\gamma-\text{CH}_3\text{Val}), 24.7$ (γ-CH₃ΔAbu), 28.3 [C(CH₃)₃], 30.5 (β-CHVal), 52.5 (OCH₃), 59.5 (α-CHVal), 80.2 [OC(CH₃)₃], 125.2 (C), 126.7 (C), 155.8 (C=O), 162.8 (C=O), 170.1 (C=O). Anal. Calcd for C₁₅H₂₅BrN₂O₅: C, 45.81; H, 6.41; N, 7.12. Found: C, 45.80; H, 6.32; N, 7.27. Boc-Val-E-Δ-Abu(β -Br)-OMe (**E-33**) was obtained as a white solid, mp 158.5– 159.0 °C from diethyl ether/*n*-hexane; ¹H NMR (300 MHz, CDCl₃) δ 0.95 (d, *J*=6.9 Hz, 3H, γ-CH₃Val), 0.99 (d, *J*=6.9 Hz, 3H, γ-CH₃Val), 1.42 (s, 9H, CH₃Boc), 2.08–2.19 (m, 1H, β-CHVal), 2.35 (s, 3H, $\gamma\text{-CH}_3\Delta\text{Abu}),~3.78$ (s, 3H, OCH_3), 3.99–4.04 (m, 1H, $\alpha\text{-CHVal}),~5.28$ (d, J=8.4 Hz, 1H, NHVal), 8.27 (s, 1H, NHΔAbu); 13 C NMR (75.4 MHz, CDCl₃) δ 18.0 (γ-CH₃Val), 19.1 (γ-CH₃Val), 25.6 (γ-CH₃ΔAbu), 28.2 [C(CH₃)₃], 30.5 (β-CHVal), 52.2 (OCH₃), 59.7 (α-CHVal), 80.4 [OC(CH₃)₃], 122.9 (C), 126.0 (C), 156.2 (C=0), 164.0 (C=0), 170.5 (C=O). Anal. Calcd for C₁₅H₂₅BrN₂O₅: C, 45.81; H, 6.41; N, 7.12. Found: C, 45.75; H, 6.38; N, 7.28.

4.3.11. tert-Butyl 2-(4-methyl-2-oxo-2H-chromen-3-ylamino)-2-oxoethylcarbamate (**34**)

Compound **34** was prepared from *E*-**32**²⁶ (90.0 mg, 0.260 mmol) according to general procedure 1 described above and heating for 3 h. Column chromatography using 50% diethyl ether/petroleum ether gave compound **34** (45.0 mg, 53%) as an oil. Crystallization from diethyl ether/petroleum ether gave a white solid, mp 110–111 °C; ¹H NMR (300 MHz, CDCl₃) δ 1.47 (s, 9H, CH₃Boc), 2.35 (s, 3H, γ-CH₃ΔAbu), 4.04 (d, *J*=5.1 Hz, 2H, CH₂Gly), 5.52 (br s, 1H, NHGly), 7.28–7.34 (m, 2H, ArH), 7.47–7.52 (m, 1H, ArH), 7.65 (d, *J*=8.4 Hz, 1H, ArH), 8.21 (br s, 1H, NH); ¹³C NMR (75.4 MHz, CDCl₃) δ 15.5 (γ-CH₃ΔAbu), 28.2 [C(CH₃)₃], 44.7 (CH₂Gly), 80.5 [OC(CH₃)₃], 116.7 (CH), 119.9 (C), 120.4 (C), 124.7 (CH), 125.2 (CH), 131.1 (CH), 144.7 (C), 151.2 (C), 156.1 (C), 159.5 (C), 168.8 (C); MS (FAB) *m*/*z* 334 (M⁺+2), 333 (M⁺+1), 332 (M⁺), 307 (M⁺–25), 289 (M⁺–(CH₃)₃), 277 (M⁺–(CH₃)₃C); HRMS *m*/*z* [M⁺+H] calcd for C₁₇H₂₁N₂O₅ 333.1450, found 333.1451.

4.3.12. tert-Butyl 3-methyl-1-(4-methyl-2-oxo-1,2-

dihydroquinolin-3-ylamino)-1-oxobutan-2-ylcarbamate (35)

Compound **35** was prepared from *E*-**33** (100 mg, 0.254 mmol) according to general procedure 1 described above and heating for 4 h 30 min. Column chromatography using chloroform gave compound **35** (57.0 mg, 60%) as a beige solid, mp 229–231 °C; ¹H NMR (300 MHz, DMSO- d_6) δ 0.92 (d, J=6.6 Hz, 3H, γ -CH₃Val), 0.98 (d, J=6.6 Hz, 3H, γ-CH₃Val), 1.39 (s, 9H, CH₃Boc), 2.02–2.09 (m, 1H, β-CHVal), 2.23 (s, 3H, γ-CH₃ΔAbu), 3.97–4.03 (m, 1H, α-CHVal), 6.84 (d, J=8.7 Hz, 1H, NHVal), 7.18–7.23 (m, 1H, ArH), 7.30 (d, J=8.1 Hz, 1H, ArH), 7.45–7.50 (m, 1H, ArH), 7.74 (d, J=8.1 Hz, 1H, ArH), 9.26 (br s, 1H, NH), 11.88 (br s, 1H, NH); ¹³C NMR (75.4 MHz, DMSO-d₆) δ 14.7 (γ-CH₃ΔAbu), 18.3 (γ-CH₃Val), 19.5 (γ-CH₃Val), 28.2 [C(CH₃)₃], 30.3 (β-CHVal), 60.3 (α-CHVal), 78.1 [OC(CH₃)₃], 115.2 (CH), 119.7 (C), 122.0 (CH), 125.0 (CH), 125.7 (C), 129.6 (CH), 136.6 (C), 140.6 (C), 155.7 (C), 159.0 (C), 170.9 (C); MS (FAB) m/z 375 (M⁺+2), 374 (M^++1) , 373 (M^+) , 318 $(M^+-(CH_3)C)$, 175 $(M^+-Boc-Val-CO)$; HRMS m/z [M⁺+H] calcd for C₂₀H₂₈N₃O₄ 374.2080, found 374.2079.

Acknowledgements

Foundation for the Science and Technology (FCT)—Portugal and FEDER (European Communautaire fund), for financial support through Centro de Química of Univ. Minho, Project POCI/QUI/ 59407/2004, for a post-doc. grant awarded to A.S.A. (SFRH/BPD/ 24548/2005) and for a Ph.D. grant awarded to R.C.C. (SFRH/BD/ 29274/2006) was acknowledged.

References and notes

- (a) Wall, M. E.; Wani, M. C.; Cook, C. E.; Palmer, K. H.; McPhail, A. T.; Sim, G. A. J. Am. Chem. Soc. **1966**, 88, 3888–3890; (b) Comins, D. L.; Nolan, J. M. Org. Lett. **2001**, 3, 4255–4257.
- 2. Josien, H.; Curran, D. P. Tetrahedron 1997, 53, 8881–8886.
- 3. Thorsett, E. D.; Latimer, L. H. Curr. Opin. Chem. Biol. 2000, 4, 377-382.
- Buchstaller, H.-P.; Siebert, C. D.; Steinmetz, R.; Frank, I.; Berger, M. L.; Gottschlich, R.; Leibrock, J.; Krug, M.; Steinhilber, D.; Noe, C. R. J. Med. Chem. 2006, 49, 864–871.
- Freeman, G. A.; Andrews, C. W., III; Hopkins, A. L.; Lowell, G. S.; Schaller, L. T.; Cowan, J. R.; Gonzales, S. S.; Koszalka, G. W.; Hazen, R. J.; Boone, L. R.; Ferris, R. G.; Creech, K. L.; Roberts, G. B.; Short, S. A.; Weaver, K.; Reynolds, D. J.; Milton, J.; Ren, J.; Stuart, D. I.; Stammers, D. K.; Chan, J. H. *J. Med. Chem.* 2004, *47*, 5923–5936.
- Cortese, N. A.; Zielger, C. B.; Hrnjez, B. J.; Heck, R. F. J. Org. Chem. 1978, 43, 2953–2958.
- 7. Cho, C. S.; Kim, J. U. Tetrahedron Lett. 2007, 48, 3775-3778.
- (a) Hecht, S. S.; Kenney, P. M. J.; Wang, M.; Trushin, N.; Agarwal, S.; Rao, A. V.; Upadhyaya, P. *Cancer Lett.* **1999**, *137*, 123–130; (b) Georgieva, M. C.; Konstantinov, S. M.; Berger, M. R. *Cancer Lett.* **2002**, *182*, 163–174.
- (a) Palmer, C. J.; Josephs, J. L. J. Chem. Soc., Perkin Trans. 1 1995, 3135–3152; (b) Kucherenko, A.; Flavin, M. T.; Boulanger, W. A.; Khilevich, A.; Shone, R. L.; Rizzo, J. D.; Sheinkman, A. K.; Xu, Z.-Q. Tetrahedron Lett. 1995, 36, 5475–5478.
- Murata, C.; Masuda, T.; Todoroki, K.; Yoshida, H.; Nohta, H.; Yamaguchi, M.; Takadate, A. Chem. Pharm. Bull. 2005, 53, 750–758.
- 11. Jusinski, L. E.; Taatjes, C. A. Rev. Sci. Instrum. 2001, 72, 2837-2838.
- 12. Raviv, U.; Klein, J. Polym. Adv. Technol. 1998, 9, 825-830.
- (a) Kadnikov, D. V.; Larock, R. C. Org. Lett. 2000, 2, 3643–3646; (b) Kadnikov, D. V.; Larock, R. C. J. Org. Chem. 2003, 68, 9423–9432.
- 14. Kadnikov, D. V.; Larock, R. C. J. Org. Chem. 2004, 69, 6772–6780.
- 15. Battistuzzi, G.; Bernini, R.; Cachi, S.; De Salve, I.; Fabrizi, G. Adv. Synth. Catal. 2007, 349, 297–302.
- Battistuzzi, G.; Cachi, S.; De Salve, I.; Fabrizi, G.; Parisi, L. M. Adv. Synth. Catal. 2005, 347, 308–312.
- Abreu, A. S.; Silva, N. O.; Ferreira, P. M. T.; Queiroz, M.-J. R. P.; Venanzi, M. Eur. J. Org. Chem. 2003, 4792–4796.
- Abreu, A. S.; Ferreira, P. M. T.; Queiroz, M.-J. R. P.; Ferreira, I. C. F. R.; Calhelha, R. C.; Estevinho, L. M. Eur. J. Org. Chem. 2005, 2951–2957.
- Abreu, A. S.; Castanheira, E. M. S.; Ferreira, P. M. T.; Queiroz, M.-J. R. P. Tetrahedron 2007, 63, 2215–2222.
- For a recent review, see: Kotha, S.; Lahiri, K.; Kashinath, D. Tetrahedron 2002, 58, 9633–9695.
- (a) Nakamura, I.; Yamamoto, Y. Chem. Rev. 2004, 104, 2127–2198; (b) Zeni, G.; Larock, R. C. Chem. Rev. 2006, 106, 4644–4680; (c) Kálai, T.; Jeko, J.; Berente, Z.; Hideg, K. Synthesis 2006, 3, 439–446.
- Abreu, A. S.; Silva, N. O.; Ferreira, P. M. T.; Queiroz, M.-J. R. P. Tetrahedron Lett. 2003, 44, 3377–3379.
- 23. Molander, G. A.; Fumagalli, T. J. Org. Chem. 2006, 71, 5743-5747.
- Abreu, A. S.; Ferreira, P. M. T.; Monteiro, L. S.; Queiroz, M.-J. R. P.; Ferreira, I. C. F. R.; Calhelha, R. C.; Estevinho, L. M. *Tetrahedron* **2004**, *60*, 11821–11828.
- Silva, N. O.; Abreu, A. S.; Ferreira, P. M. T.; Monteiro, L. S.; Queiroz, M.-J. R. P. Eur. J. Org. Chem. 2002, 2524–2528.
- Ferreira, P. M. T.; Monteiro, L. S.; Pereira, M. G.; Ribeiro, L.; Sacramento, J.; Silva, L. Eur. J. Org. Chem. 2007, 5934–5949.
- Ferreira, P. M. T.; Maia, H. L. S.; Monteiro, L. S.; Sacramento, J. J. Chem. Soc., Perkin Trans. 1 1999, 3697–3703.